JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
127.55
-0.17 (-0.13%)
At close: 4:00PM EDT

127.60 +0.05 (0.04%)
After hours: 5:26PM EDT

Stock chart is not supported by your current browser
Previous Close127.72
Open127.63
Bid127.52 x 100
Ask127.55 x 500
Day's Range126.89 - 128.27
52 Week Range121.35 - 148.32
Volume5,958,309
Avg. Volume8,228,940
Market Cap342.171B
Beta0.59
PE Ratio (TTM)269.09
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target EstN/A
Trade prices are not sourced from all markets
  • Kentucky Governor Bevin: I'm not on board with JNJ opioid...
    CNBC Videosyesterday

    Kentucky Governor Bevin: I'm not on board with JNJ opioid...

    Kentucky Governor Matt Bevin discusses his state District Attorney suing Johnson & Johnson for contributing to the opioid epidemic through deceptive marketing.

  • Trump touts economy as stocks rally
    Fox Business Videos2 days ago

    Trump touts economy as stocks rally

    Wall Street Journal columnist Veronica Dagher, Fox News political contributor Tammy Bruce and Fox News contributor Robert Wolf on the strength of the U.S. economy and how President Trump’s tax cuts have impacted consumers.

  • Drug Division Drives Johnson & Johnson
    Morningstar2 days ago

    Drug Division Drives Johnson & Johnson

    We are increasing our fair value estimate after better that expected earnings but see the stock as fairly valued today.

  • Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
    Zacks3 hours ago

    Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

    Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

  • 3 Drugs That Are Moving the Needle at Johnson & Johnson
    Motley Fool22 hours ago

    3 Drugs That Are Moving the Needle at Johnson & Johnson

    Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.

  • Barrons.comyesterday

    After the Bell: Dow Drops 38 Points Because…IBM

    The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.

  • Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
    CNBCyesterday

    Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'

    "I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.

  • Reutersyesterday

    Kentucky accuses J&J of contributing to opioid epidemic

    Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction. The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic.

  • MarketWatchyesterday

    IBM and J&J stocks cut 100 points from Dow industrials in early trading

    The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.

  • Location revealed: Johnson & Johnson institute's new HQ to go in Lake Nona's Medical City
    American City Business Journalsyesterday

    Location revealed: Johnson & Johnson institute's new HQ to go in Lake Nona's Medical City

    This $18 million building will be next to the Sanford Burnham Prebys Medical Discovery Institute in southeast Orlando.

  • The resume of the future will tell employers who you are, and not just what you’ve done
    Quartzyesterday

    The resume of the future will tell employers who you are, and not just what you’ve done

    Resumes are a poor proxy for a human being. Whether on paper or LinkedIn, they may tell an employer about a job seeker’s experience and credentials, but they’re frustratingly silent about almost everything else. They have virtually nothing to say about a candidate’s personality, or their character, or their ability to persuade and communicate—all soft…

  • The Wall Street Journal2 days ago

    [$$] Johnson & Johnson Raises Sales Outlook

    Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices. J&J said it planned to cut costs in its supply chain by $600 million to $800 million a year by 2022. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.

  • Reuters2 days ago

    U.S. drug agency proposes rules to rein in opioid manufacturing

    The U.S. government on Tuesday proposed tightening rules governing the amount of prescription opioid painkillers that drugmakers can manufacture in a given year, in hopes of reining in the deadly opioid epidemic. The Drug Enforcement Administration's proposed changes to its regulations over addictive drug manufacturing quotas were announced by Attorney General Jeff Sessions. The plan could sharply reduce the annual production of painkillers.

  • What to Look for as First-Quarter Earnings Hit Around the Globe
    Bloomberg2 days ago

    What to Look for as First-Quarter Earnings Hit Around the Globe

    Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.

  • Associated Press2 days ago

    UnitedHealth and Alphabet climb; Tesla and Comerica skid

    Stocks that moved substantially or traded heavily Tuesday: UnitedHealth Group Inc., up $8.23 to $238.55 The health insurer raised its annual profit forecast after a strong first quarter. Tesla Inc., down ...

  • Wall Street rises on earnings hopes, Netflix soars
    Reuters2 days ago

    Wall Street rises on earnings hopes, Netflix soars

    U.S. stock indexes rallied on Tuesday on broad-based gains while Netflix and UnitedHealth earnings impressed investors and boosted optimism about the U.S. corporate reporting season. Shares in Netflix (NFLX.O), the first of Wall Street's leading momentum stocks to report earnings, rose 9 percent to close at a record high after the video-streaming pioneer smashed analysts' quarterly subscriber estimates. Amazon.com (AMZN.O) was the S&P's biggest boost with a 4 percent jump, helped by Netflix results but also by signs the U.S. Supreme Court is hesitant to let states force out-of-state online retailers to collect sales taxes on purchases.

  • J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs
    Investor's Business Daily2 days ago

    J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs

    Johnson & Johnson nudged its 2018 sales guidance higher Tuesday as demand for cancer drugs surged in the first quarter, even as its blockbuster Remicade continued to face competitive pressure.

  • TheStreet.com2 days ago

    Dow Jumps Over 200 Points; S&P 500 and Nasdaq Also Finish Higher

    Stocks rise on Tuesday as investors react to strong earnings from Goldman Sachs and Netflix.

  • Reuters2 days ago

    J&J raises sales forecast but keeps profit outlook unchanged; shares drop

    The healthcare conglomerate, whose stock had climbed about 3 percent over the previous six days, reported better-than-expected profit in the first quarter, helped by strong demand for its cancer treatments. J&J said it was not revising its earnings forecast higher for the year because certain divestments it previously expected to make this year might be pushed into 2019. "I'm definitely surprised by the stock reaction," said Gabelli Funds portfolio manager Jeff Jonas.

  • Why Geron Corporation's Stock Is Heading Higher Today
    Motley Fool2 days ago

    Why Geron Corporation's Stock Is Heading Higher Today

    Geron's experimental blood cancer drug remains a top priority for the pharma behemoth Johnson & Johnson.

  • Johnson & Johnson Stock Dips Despite Q1 Earnings Beat
    InvestorPlace2 days ago

    Johnson & Johnson Stock Dips Despite Q1 Earnings Beat

    JNJ stock is down today despite the company’s strong earnings per share of $2.06 for the first quarter of the year. This is an increase over Johnson & Johnson’s earnings per share of $1.83 from the same period of the year prior. It also beats out Wall Street’s earnings per share estimate of $2.00 for the quarter.

  • Johnson & Johnson (JNJ) Q1 2018 Earnings Conference Call Transcript
    Motley Fool2 days ago

    Johnson & Johnson (JNJ) Q1 2018 Earnings Conference Call Transcript

    JNJ earnings call for the period ending March 31, 2018.

  • J&J raises sales forecast but keeps profit outlook unchanged; shares drop
    Reuters2 days ago

    J&J raises sales forecast but keeps profit outlook unchanged; shares drop

    The healthcare conglomerate, whose stock had climbed about 3 percent over the previous six days, reported better-than-expected profit in the first quarter, helped by strong demand for its cancer treatments. J&J said it was not revising its earnings forecast higher for the year because certain divestments it previously expected to make this year might be pushed into 2019. "I'm definitely surprised by the stock reaction," said Gabelli Funds portfolio manager Jeff Jonas.

  • Stocks surge on earnings, China to ease foreign auto rules
    Yahoo Finance2 days ago

    Stocks surge on earnings, China to ease foreign auto rules

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

  • Novartis’s 1Q18: Analysts Expect Revenue Growth
    Market Realist2 days ago

    Novartis’s 1Q18: Analysts Expect Revenue Growth

    Analysts expect Novartis’s (NVS) revenue to rise ~8.8% to $12.6 billion in 1Q18 following growth in operating revenues across all three of its segments during the quarter.